FDG Uptake on Positron Emission Tomography Correlates with Survival and Time to Recurrence in Patients with Stage I Non–Small-Cell Lung Cancer  by Kwon, Woocheol et al.
Copyright © 2015 by the International Association for the Study of Lung Cancer
897Journal of Thoracic Oncology ®  •  Volume 10, Number 6, June 2015
Introduction: Patients with stage I non–small-cell lung cancer 
(NSCLC) have a wide variation in outcomes, most likely because 
there are undetected metastases at presentation. We retrospectively 
reviewed patients with early stage lung cancer to determine if FDG 
uptake of the primary tumor as measured on positron emission 
tomography (PET) at the time of diagnosis was associated with over-
all survival (OS) or time to recurrence (TTR).
Methods: We reviewed the Tumor Registry at our institution and 
identified 336 consecutive patients diagnosed with stage I NSCLC 
over a 5-year period who underwent an FDG-PET/computed tomog-
raphy within 90 days before surgery. Kaplan–Meier curves were 
used to describe the survival and TTR experience within subgroups 
defined by PET maximum standardized uptake value (SUVmax). 
Cox proportional hazards model was used to assess the impact of 
PET SUVmax as a continuous variable on OS and TTR. Logistic 
regression was used to analyze the effect of SUVmax on dichoto-
mized outcomes.
Results: Three hundred thirty-six consecutive patients (176 women 
and 160 men) with stage I NSCLC were retrospectively reviewed. 
Mean SUVmax was 9.2 ± 6.9 (range 0.6–30.3). The hazard or risk of 
dying and recurrence increased significantly as SUVmax increased 
(p = 0.0008 and 0.024, respectively).
Conclusions: Preoperative FDG uptake in the primary tumor in 
patients with stage I disease is associated with OS and TTR. This 
may be useful in identifying early stage patients who may benefit 
from more aggressive therapy after surgical resection.
Key Words: Non–small-cell lung cancer, FDG-PET, risk stratifica-
tion, imaging biomarkers.
(J Thorac Oncol. 2015;10: 897–902)
The current clinical staging system for lung cancer is pri-marily based on radiological findings and is still subop-
timal despite recent revisions of guidelines to address wide 
variations in phenotype among the same stage patient.1,2 This 
problem is most evident in patients with clinical stage I non–
small-cell lung cancer (NSCLC). These patients have at best 
a 60% 5-year survival rate after surgical resection, suggesting 
that many stage I patients have undetectable metastasis at the 
time of presentation.3,4 There is a clear need for more accurate 
stratification, which could be used to influence and rationally 
design therapeutic strategies. A diagnostic test that could pre-
dict which early stage lung cancer patients will recur would 
change clinical management and potentially improve out-
comes. Ostensibly, patients who have a cancer with an aggres-
sive phenotype would need immediate therapy whereas others 
could avoid treatment-related toxicity and complications.
Several prior studies have explored the use of 2-deoxy-
2-(18F) fluoror-D-glucose (FDG) positron emission tomogra-
phy (PET) in stage I NSCLC, but these are reported based 
on previous T descriptor and do not specifically evaluate its 
ability to predict time to recurrence (TTR).5–10 We performed 
a retrospective review of 336 consecutive patients with stage 
I NSCLC who underwent FDG-PET at initial presentation to 
determine if FDG uptake as measured by the standardized 
uptake values (SUVmax) was associated with overall survival 
(OS) or correlated with TTR in patients with stage I NSCLC.
MATERIALS AND METHODS
Study Population
This single-institution retrospective study was approved 
by our Institutional Review Board and complies with the 
Health Insurance Portability and Accountability Act. Informed 
consent was waived for this review.
We searched the tumor registry at our institution and 
identified all consecutive patients diagnosed with stage I 
NSCLC between January 2005 and December 2010. The 
inquiry of patients was ended in 2010 so that there would be a 
sufficient follow-up period. Patients included met the follow-
ing criteria: a pathological diagnosis of a new stage I NSCLC, 
an FDG-PET study within 90 days of histologic diagnosis and 
before surgery, and at least 3 weeks of follow-up. A clinical 
stage at presentation was assigned according to the 7th edi-
tion of the tumor, node, metastasis (TNM) staging system 
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developed by the International Association for the Study of 
Lung Cancer and approved by the American Joint Committee 
on Cancer and International Union Against Cancer, which 
replaced previous staging systems in 2010.11
There were 336 patients, 176 women and 160 men, with 
a mean age at diagnosis of 68 ± 9 years (range 30–86 years), 
who met these eligibility criteria. Two hundred eighty-eight 
patients had PET before histologic confirmation with a mean 
of 24 days (range, 1–90 days), 44 patients had PET after histo-
logic confirmation with a mean of 20 days (range, 1–65 days), 
and four patients had PET on the same day of pathologic 
diagnosis.
Tumor histologic cell type by the International 
Association for the Study of Lung Cancer/World Health 
Organization classification,3,12 pathological stage, site(s) 
and dates of recurrence, and treatment were obtained from 
the patient’s medical record. Initial histologic diagnosis was 
achieved by transthoracic needle aspiration (n = 38), trans-
bronchial biopsy (n = 20), or at the time of surgical resection 
(n = 275); for three patients, the initial means of histologic 
diagnosis were not specified. A wide range of histologic sub-
types was included. For example, of 185 adenocarcinomas 
(ACs), histologies were AC not otherwise specified (n = 110), 
bronchioalveolar (n = 33), mixed subtypes (n = 19), acinar 
(n = 9), mucinous (n = 7), papillary (n = 6), and signet ring 
(n = 1). Patient data are shown in Table 1.
PET/CT Imaging
Patients received nothing by mouth for at least 4 
hours preceding the PET/computed tomography (CT) 
scan. Blood glucose was measured to assure that it was 
within the normal range, and if patients had received insu-
lin, the scan was delayed for 4 hours. Patients were then 
injected intravenously with 0.14 to 0.18 mCi/kg FDG and 
placed in a darkened quiet room for a minimum uptake 
period of one hour.
The CT scan was performed first, from the skull base to 
mid thighs at end-tidal respiration. Intravenous contrast was 
not administered unless specifically requested by the order-
ing physician as part of a diagnostic chest/abdomen/pelvis CT. 
Scan parameters were as follows: 3.75 mm collimation, 120 
kVp, 30 to 300 mA (when automatic tube current modulation 
was employed), and noise parameter of 20.
PET images were then acquired from skull base to mid 
thighs, using the following scanners: a GE Discovery ST 
from January 2005 through October 2006, a GE Discovery 
STE from November 2006 through January 2009, and both 
GE Discovery STE and GE Discovery 690 scanners from 
February 2009 through 2010 (GE Healthcare, Wauwatosa, 
WI). PET data were acquired in 2D or 3D mode. Time per bed 
position varied depending upon patient weight; for 3D mode 
this was as follows: 2:00 minutes for 70–80 kg, 2:30 min-
utes for 81–90 kg, 3:00 min for 91–113 kg, 3:30 minutes for 
114–136 kg, and 4:00 minutes for more than 136 kg.
Images were reconstructed with two iterations of the 
ordered subsets expectation maximization algorithm, incor-
porating corrections for detector sensitivity, dead time, scat-
tered events, random events, and attenuation, based on CT. 
Time-of-flight information was incorporated on Discovery 
690 images. Attenuation-corrected PET images were reviewed 
along with the CT images. Maximum standardized uptake 
value (SUVmax) was computed using a spherical region of 
interest (ROI) and the formula (mCi/ml in ROI injected activ-
ity in mCi/ bodyweight [g]).
Treatment and Follow-up
Treatment consisted of surgical resection in 325 patients, 
stereotactic body radiation in 9 patients, and local radioabla-
tive therapy in 2 patients. Adjuvant chemotherapy was given 
in 28 patients and neoadjuvant therapy in 9 patients.
OS was defined as the time interval from date of initial 
histologic diagnosis until death, or until patients were cen-
sored at the date of last follow-up. Recurrence was defined as 
any unequivocal occurrence of new metastatic focus or foci in 
a patient who had been without known metastatic disease after 
initial therapy, as documented by clinical evaluation, includ-
ing imaging studies. The site of the first cancer recurrence 
and the time interval between the initial diagnosis and cancer 
recurrence (i.e., TTR) were determined.
Statistical Analysis
The Cox proportional hazards model was used to assess 
the relationship of PET SUVmax (uncategorized) and TTR, 
as well as OS. TTR was censored at the time of last follow-up 
TABLE 1.  Patient Characteristics
Number Percent
Total number of patients 336
Sex
  Female 176 52
  Male 160 48
Stage (7th edition)
  T1N0 1 0.3
  T1aN0 122 36
  T1aNx 1 0.3
  T1b 1 0.3
  T1bN0 75 22
  T1bNx 2 0.6
  T2aN0 134 40
Age
  Mean (standard deviation) 68 (9.2)
  Range 30–86
Histology
  Adenocarcinoma 185 55
  Adenosquamous carcinoma 3 0.9
  Carcinoid tumor 6 1.8
  Carcinoma of salivary gland type 2 0.6
  Carcinoma with pleomorphic,  
 sarcomatoid, or sarcomatous elements
4 1.2
  Large cell carcinoma 21 6.3
  Non–small-cell carcinoma, not otherwise  
 specified
10 3
  Squamous cell carcinoma 105 31
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if the patient remained alive and without recurrence at last 
follow-up. In addition, TTR was censored at death if the patient 
died without recurrence. OS was defined as the time between 
initial diagnosis and death, regardless of cause of death. OS 
was censored at last follow-up for patients remaining alive.
Schoenfeld and Martingale residuals were used to 
assess the proportional hazards assumption and the functional 
form of the predictor. Kaplan–Meier curves were generated to 
graphically display the OS and TTR experience within patient 
subgroups defined by PET SUVmax. Logistic regression was 
used to assess the association between individual predictors 
(PET SUVmax) and dichotomized outcome (recur/no recur 
and alive/dead).
Analysis of variance was used to compare PET SUVmax 
of the major histologic categories (AC, squamous cell carci-
noma [SCC]) and all other histologies (other). Cox model 
statistics were used to determine whether the relationship 
between SUVmax and outcomes (TTR, survival) observed in 
the entire patient population held true for each of these three 
histologic groups.
RESULTS
Study Population
The median follow-up period was 5.1 years (95% con-
fidence interval: 4.5, 5.5). At time of last follow-up, 134 of 
336 patients had died and 90 had recurred (40% and 27%, 
respectively). Median TTR was 6.9 years (95% confidence 
interval: 5.3,∞), whereas the median survival was 7.8 years 
(95% confidence interval: 6.5, ∞). Among the 90 patients who 
developed recurrent disease, 44 (49%) had distant recurrence, 
43 (48%) had locoregional recurrence, and three recurred 
at an unspecified site (3%). Among the patients with distant 
recurrence, the TTR ranged between 0.15 and 6.3 years, with 
a median of 1.0 year; whereas among those who had a local 
recurrence, the time to local recurrence ranged between 0.2 
and 8.6 years, with a median of 3.2 years. Two hundred forty-
six patients (121 males and 125 females, with mean age of 68 
years) did not recur (246 of 336, 73%). Of these patients, 170 
(69%) remained alive at last follow-up, and 76 (31%) patients 
died from other causes without evidence of disease.
SUVmax and Recurrence
Cox model analyses show that PET SUVmax (uncat-
egorized) has a significant association with TTR (p = 0.024). 
For each unit increase in PET SUVmax, the hazard increases 
by a factor of 1.034 (i.e., hazard ratio = 1.033 with 95% con-
fidence interval of 1.004–1.062). Kaplan–Meier curves that 
describe TTR within each of four patient groups defined by 
quartiles of the distribution of PET SUVmax levels are dis-
played in Figure 1.
Given that the original question was posed as dichot-
omous outcomes (recurrent or non-recurrent), we also used 
logistic regression to examine the effect of PET SUVmax 
on recurrence status separate from length of follow-up. 
That analysis did not show a statistically significant rela-
tionship between PET SUVmax levels and recurrence sta-
tus (p = 0.223).
SUVmax and Survival
Cox model analyses show that as PET SUVmax levels 
(uncategorized) increase, there is a significant increase in the 
hazard of dying (p = 0.0008). For each unit increase in PET 
SUVmax, the hazard increases by a factor of 1.039 (i.e. hazard 
ratio = 1.039 with 95% confidence interval of 1.016–1.063). 
Kaplan–Meier curves describing survival within each of four 
patient groups defined by quartiles of the distribution for PET 
SUVmax levels are provided in Figure 2.
We also used logistic regression to examine the effect 
of PET SUVmax on alive/dead status separate from length 
of follow-up. That analysis also showed a statistically sig-
nificant relationship between PET SUVmax levels and alive/
dead status (p = 0.011).
FIGURE 1.  Kaplan–Meier curves for quartiles of primary 
tumor SUVmax demonstrate increased time to recurrence for 
patients with lower SUVmax. SUVmax, maximum standard-
ized uptake value on positron emission tomography.
FIGURE 2.  Kaplan–Meier curves for quartiles of primary 
tumor SUVmax demonstrate improved survival for patients 
with lower SUVmax. SUVmax, maximum standardized uptake 
value on positron emission tomography.
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These results show that there is a statistically significant 
relationship between PET SUVmax and survival, as well as 
between PET SUVmax and TTR.
Subgroup Analysis by Histology
The mean and range for SUVmax for the most preva-
lent histologies (AC [n = 185], SCC [n = 105], and “other”  
[n = 46]) were as follows: for AC, mean = 6.7 ± 5.9 and range 
0.6–30; for SCC, mean = 12.6 ± 7.1, range 1.1–30; and for 
“other,” mean = 11.2 ± 6.5, range 0.9–24. Analysis of variance 
demonstrated that the mean SUVmax was significantly lower 
for AC than for SCC and “other” histologies (p < 0.0001).
Cox model statistics demonstrated that SUVmax was 
significantly associated with TTR within the AC and “other” 
histologic groups (p = 0.003 and 0.002), but not for SCC 
(p = 0.578). The effect of SUVmax on TTR was significantly 
different among the three histologic groups (p = 0.027), as 
displayed in Table 2.
Cox model statistics demonstrated that SUVmax was 
significantly associated with OS for all histologic subgroups 
(p = 0.064 for AC, p = 0.004 for SCC, and p = 0.003 for 
“other”). The relationship observed between SUVmax and OS 
did not differ significantly among the three groups, as shown 
in Table 3.
DISCUSSION
With advances in CT screening and early detection, it 
is expected that more patients with lung cancer will be diag-
nosed with early stage disease with a wide range of phe-
notypes. Most of these patients will be treated by primary 
surgical resection, as there are no clear data that additional 
therapy prolongs survival. Although a recent meta-analysis of 
cisplatin-based adjuvant therapy showed a 5% benefit in sur-
vival in stages I–III lung cancer, there was an increased early 
death rate and trend toward harm associated with the adjuvant 
therapy.13 Currently, a mechanism to identify patients who will 
develop recurrence does not exist, as is the case with many 
other types of tumors. Improving outcomes will ultimately 
depend upon a better understanding of the tumor’s biological 
behavior.
The current study was performed in an effort to deter-
mine if FDG uptake in patients with stage I NSCLC was asso-
ciated with poorer OS or could suggest which patients were at 
risk for early recurrence. This information might then be used 
to potentially alter treatment up-front rather than using a “wait 
and watch” approach after surgical resection. If an imaging 
biomarker such as FDG uptake could predict which patients 
will develop early recurrence, then adjuvant chemotherapy 
could be targeted to only those patients who are most likely to 
benefit, thereby sparing others unnecessary toxicity.
A 2008 meta-analysis confirmed that increased SUV of 
the primary tumor is a poor prognostic factor in patients with 
stages I–III NSCLC; however, it also found poor reproducibil-
ity because of the lack of standardization of acquisition and 
processing protocols and heterogeneity in the SUV thresh-
olds used (SUV max ranging from 2.5 to 20); such factors 
likely have impeded the use of SUVmax as a discriminator in 
routine practice.14 In a retrospective cohort study, Goodgame 
et al.7 showed in 136 NSCLC of nonbronchioalveolar cell his-
tologies that patients with preoperative PET SUVmax above 
the median value of 5.5 had poorer survival and recurrence 
rates compared with those below 5.5. A 2009 meta-analysis 
focusing on stage I NSCLC found that high SUVmax on pre-
operative PET was a poor prognostic factor.9
TABLE 2.  SUVmax and Time to Recurrence by Histologic Group
Parameter DF Parameter Estimate Standard Error χ2 P Value HR
95% Confidence 
Interval
SUVmax within 
adenocarcinoma group
1 0.056 0.018 9.16 0.003 1.057 1.020, 1.096
SUVmax within 
squamous group
1 0.010 0.018 0.310 0.578 1.010 0.974, 1.047
SUVmax among “other” 
group
1 0.066 0.022 9.179 0.002 1.068 1.023, 1.114
SUVmax, maximum standardized uptake value on positron emission tomography; DF, degrees of freedom; HR, hazard ratio.
TABLE 3.  SUVmax and Overall Survival by Histologic Group
Parameter DF Parameter Estimate Standard Error χ2 P Value HR
95% Confidence 
Interval
SUVmax within 
adenocarcinoma 
group
1 0.032 0.017 3.417 0.064 1.033 0.998, 1.069
SUVmax within 
squamous group
1 0.036 0.013 8.302 0.004 1.037 1.012, 1.063
SUVmax among “other” 
group
1 0.054 0.018 9.134 0.003 1.056 1.019, 1.094
SUVmax, maximum standardized uptake value on positron emission tomography; DF, degrees of freedom; HR, hazard ratio.
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Tumor size is also considered to be an independent 
prognostic factor. Downey et al., 6 in a study of patients with 
NSCLC including carcinoid, showed that tumor size greater 
than 3 cm was a predictor of 2-year survival, and the addi-
tion of SUVmax greater than 9 to these size criteria optimally 
stratified patients into a group with poor 3-year survival.7,8 
These and other data are based on the 6th edition of TNM sys-
tem, and we hypothesized that more relevant results may be 
obtained concerning the relationship of recurrence and OS 
with SUVmax in stage I NSCLC by using the 7th TNM. Nair 
et al.10 recently reported in a retrospective study of 75 Stage 
IA lung cancers that SUVmax correlated with poorer survival.
Our results show that there is a statistically significant 
relationship between PET SUVmax and survival, and between 
SUVmax and TTR, with decreasing SUVmax correlating with 
improved survival and longer TTR. Instead of a single cut-
off SUVmax value used in other analyses, we used a quar-
tile analysis, which reflects the continuously increasing risk 
of recurrence and death with higher SUV. From the Kaplan–
Meier curves, it can be estimated that at 2 years, 22.5% of 
patients will have recurred with primary tumor SUVmax ≥7.2 
whereas only 8% with less than 3.4 SUVmax. Forty-one per-
cent of patients will remain alive with SUVmax between 7.2 
and 14.2, and 77% will be alive with SUVmax less than 3.4 at 
5 years. There was no relationship between PET SUVmax and 
recurrence as a dichotomous variable separate from length of 
follow-up.
Prognosis in resected stage I lung cancer has also been 
described as a function of histologic grade,15 of angiolym-
phatic and pleural invasion,16 and of preoperative FEV(1)% 
(forced expiratory volume in 1 second/forced vital capacity × 
100).17 The histologic type of NSCLC has not been found to 
greatly impact prognosis above other factors, however18; we 
performed a subgroup analysis to test this assumption in our 
patient population. We determined that AC had a significantly 
lower metabolic activity than SCC and “other” histologies, 
consistent with prior reports.19 This may reflect the inclusion 
of the more indolent forms of the AC subtype in our patient 
population, which are typically low in FDG uptake.
We found that SUVmax of AC and “other” histologies 
excluding SCC was significantly associated with TTR, but no 
such association was found in patients with SCC. Although 
this may be secondary to the biases inherent in a retrospective 
analysis that limit the assessment of true TTR or smaller sam-
ple sizes in this subgroup analysis, it may alternatively reflect 
an inherent difference in tumor biology of SCC. It is known 
that squamous and non-squamous NSCLC are distinctly dif-
ferent entities, with SCC more correlated with smoking his-
tory and cavitary appearance on CT, as well as uniformly 
expressing TAp63, a p53-like tumor suppressor, and the onco-
gene Np63, when compared with AC. Moreover, SCC dem-
onstrate more frequent expression of melanoma-associated 
antigens and have more extensive infiltration of CD8+ T cells 
than non-squamous tumors.20 The possibility that these bio-
logic factors may explain the lack of usefulness of SUVmax 
for predicting TTR in SCC deserves further study.
Regardless, our analysis showed that SUVmax was sig-
nificantly associated with OS, no matter whether the histol-
ogy was AC, SCC, or “other.” Interestingly, the nature of the 
association with SUVmax and OS for SCC did not differ from 
AC, which is unexpected given that the SUVmax of SCC was 
significantly higher. These results contradict those of Shimizu 
et al., who recently reported that higher SUVmax correlated 
with poorer survival in AC, but not in SCC.21
The importance of this association between tumor 
SUVmax and outcomes is underscored by the finding that 
SUVmax at time of diagnosis correlates with survival in stage 
I NSCLC, but not in advanced stage (III and IV) cancers.22 
Use of FDG uptake as a biomarker for patient stratification 
would seem to be most appropriate at time of surgery when 
adjuvant therapy is contemplated, as opposed to later, after the 
tumor has metastasized/recurred and potentially evolved its 
biologic phenotype.
Strengths of our study include a large number of patients 
over a 5-year period with up to 10 years of follow-up, as well 
as a wide cross section of histological cell types and use of the 
7th TNM staging system. Our study also reflects the hetero-
geneity of clinical practice: although most patients received 
surgical resection, radioablative therapies were also used for 
poor surgical candidates, and some patients received adjuvant 
or neoadjuvant chemotherapy.
The primary limitation of our study is its retrospec-
tive nature. Patients were followed at different intervals, 
some were lost to follow-up, and some may potentially have 
recurred after the time of last censoring. Although this bias 
is likely responsible for the lack of correlation observed 
between SUVmax and TTR separate from length of follow-
up, the inverse correlation between SUVmax and survival as a 
dichotomous outcome separate from length of follow-up was 
maintained, indicating the strength of this finding. Although 
tumor size was taken into account when assigning a stage, 
we did not directly incorporate it into the outcome analysis. 
It is also likely that for small tumors less than 2 cm that the 
SUVmax was underestimated, because of volume averaging 
effects inherent in PET. In addition, variation in technical fac-
tors, such as blood glucose level and differences in scanners 
and acquisition parameters, may have some effect on results.
In conclusion, our study demonstrated that PET 
SUVmax of stage I NSCLC at diagnosis is predictive of 
survival and TTR. This parameter may serve as a biomarker 
to guide selection of patients for adjuvant chemotherapy or 
other more aggressive therapies. Prospective treatment trials 
in patients with early stage lung cancer incorporating tumor 
SUVmax should be considered.
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